Editas Medicine Inc (NAS:EDIT)
$ 1.199 -0.011 (-0.91%) Market Cap: 99.88 Mil Enterprise Value: -126.72 Mil PE Ratio: 0 PB Ratio: 0.57 GF Score: 46/100

Editas Medicine Inc, Apellis Pharmaceuticals Inc and Rigel Pharmaceuticals Inc at Citi Biotech Conference Transcript

Sep 05, 2019 / 12:00PM GMT
Release Date Price: $24.19 (+4.45%)
Yigal Dov Nochomovitz
Citigroup Inc, Research Division - Director

Let's kick it off. So welcome back everyone for Day 2 of the Citi Biotech Conference. It's my great pleasure to have with me 3 distinguished management members: from Apellis, the CEO, Cedric Francois; from Editas Medicine, Charlie Albright, the Chief Scientific Officer; and of course, in the middle Raul Rodriguez, the President and CEO of Rigel Pharmaceuticals. So welcome all of you. Thanks for participating.

Questions & Answers

Yigal Dov Nochomovitz;Cedric Francois
Citigroup Inc, Research Division - Director;Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO

So maybe just to kick off, it would be very helpful since your -- I titled this benign hematology, but there's slight differences in the therapeutic focuses for all 3 of your companies. So maybe it would be helpful just to start out giving us a sense of the unmet need in PNH, in ITP and then in the hemoglobinopathies, beta thal and sickle cell just at a high level, that would be perfect.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot